Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Zack Pemberton-Whiteley"'
Autor:
Myrto Lee, Hugo Larose, Martin Gräbeldinger, Jon Williams, Anne-Marie Baird, Susan Brown, Johannes Bruns, Russell Clark, Javier Cortes, Giuseppe Curigliano, Andrea Ferris, Louis P. Garrison, Y.K. Gupta, Ravindran Kanesvaran, Gary Lyman, Luca Pani, Zack Pemberton-Whiteley, Tomas Salmonson, Peter Sawicki, Barry Stein, Dong-Churl Suh, Galina Velikova, Jens Grueger
Publikováno v:
Health Policy Open, Vol 6, Iss , Pp 100116- (2024)
The move toward early detection and treatment of cancer presents challenges for value assessment using traditional endpoints. Current cancer management rarely considers the full economic and societal benefits of therapies. Our study used a modified D
Externí odkaz:
https://doaj.org/article/e4d6e9cf3a8d4b7d88dee937863945b9
Autor:
Fabian Lang, Zack Pemberton-Whiteley, Joannie Clements, Cristina Ruiz, Delphine Rea, Lisa Machado, Naoto Takahashi, Sung-Ho Moon, Andrew P Grigg, Cornelia Borowczak, Peter Schuld, Pauline Frank, Cristina Constantinescu, Carla Boquimpani, Jorge Cortes
Publikováno v:
HemaSphere, Vol 7, p e8318962 (2023)
Externí odkaz:
https://doaj.org/article/cf743e5dc7cd41f18b5c3bb8ede24c7e
Autor:
Samantha Nier, Zack Pemberton-Whiteley, Jan Geissler, Anne-Pierre Pickaert, Sophie Wintrich, Cheryl Petruk, Esther Nathalie Oliva, Tatyana Ionova, Sam Salek
Publikováno v:
HemaSphere, Vol 7, p e828458b (2023)
Externí odkaz:
https://doaj.org/article/82c6aeae07304b0c80ac9b79030aca55
Autor:
Samantha Nier, Zack Pemberton-Whiteley, Nick York, Kathryn Huntley, Deborah Baker, Michael Rynne, Nicole Schroeter, Denis Costello, Lidija Pecova, Esther Natalie Oliva, Tatyana Ionova, Sam Salek
Publikováno v:
HemaSphere, Vol 7, p e038702e (2023)
Externí odkaz:
https://doaj.org/article/b6d8bb38e7fb400fa1447b4853f8d091
Autor:
Zack Pemberton-Whiteley, Samantha Nier, Jan Geissler, Sophie Wintrich, Bregje Verhoeven, Rita O. Christensen, Sam Salek, Esther Natalie Oliva, Tatyana Ionova, Jennie Bradley
Publikováno v:
Journal of Patient-Centered Research and Reviews, Vol 10, Iss 1, Pp 21-30 (2023)
Purpose: The Acute Leukemia Advocates Network (ALAN) sought to determine which factors are most associated with poor quality of life (QoL) in patients with acute leukemia and to determine key issues and unmet needs through administration of an online
Externí odkaz:
https://doaj.org/article/24b66c02e236467db5ddddc70cb05794
Autor:
Zack Pemberton-Whiteley, Samantha Nier, Jan Geissler, Sophie Wintrich, Anne-Pierre Pickaert, Sam Salek, Esther Natalie Oliva, Tatiana I. Ionova, Jennie Bradley
Publikováno v:
Blood. 140:13273-13275
Autor:
Zack Pemberton-Whiteley, Samantha Nier, Nick York, Deborah Baker, Michael Rynne, Nicole Schroeter, Denis Costello, Lidija Pecova, Esther Natalie Oliva, Tatiana I. Ionova, Sam Salek, Jennie Bradley
Publikováno v:
Blood. 140:5258-5259
Autor:
Aurelie Meunier, Kun Zhao, Jasmine Farrington, Koonal Shah, Wolfgang Greiner, Louis P. Garrison, Louise Longworth, Zack Pemberton-Whiteley, Stephen Palmer, Doug Coyle, Johann-Matthias Graf von der Schulenburg, Isabelle Durand-Zaleski, Anne-Sophie Moutié, Jie Shen, Doug Sproule, Mark Ratcliffe
This last decade has been marked by significant advances in the development of cell and gene (C&G) therapies, such as gene targeting or stem cell-based therapies. C&G therapies offer transformative benefits to patients but present a challenge to curr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a131b94d8b0cb854b38416af70f322f8
https://doi.org/10.1007/s10198-020-01212-w
https://doi.org/10.1007/s10198-020-01212-w
Autor:
Felice Bombaci, Nigel B. Deekes, Jennifer A. Bradley, Bahija Gouimi, Jan Geissler, Zack Pemberton-Whiteley, Rita I O Christensen, Giora Sharf, Celia Marin, Mina Daban
Publikováno v:
Leukemia
In CML, treatment-free remission (TFR) refers to having a stable deep molecular response without the need for ongoing tyrosine kinase inhibitor treatment. Whilst recommendations exist about the technical management of stopping and re-starting therapy
Autor:
Virginia Pilipovic, Nigel B. Deekes, Cristina Constantinescu, Zack Pemberton-Whiteley, Carla Boquimpani, Naoto Takahashi, Delphine Rea, Pauline Frank, Lisa Machado, Cristina Pérez Ruiz, Joannie Clements, Sung-Ho Moon, Fabian Lang, Andrew Grigg, Merula Steagall, Jorge E. Cortes, Cornelia Borowczak
Publikováno v:
Blood. 138:4986-4986
Background A significant proportion (up to 37%) of patients (pts) with chronic phase (CP) CML experience either resistance or intolerance to first-line tyrosine kinase inhibitor (TKI) therapy within 5 years and transition to other treatment options(H